Targeted Anticoagulation Therapy to Reduce Inflammation and Cellular Activation in Long-term HIV Disease
Status:
Completed
Trial end date:
2018-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effects of pharmacologic FXa inhibition (via
edoxaban 30 mg daily) on inflammation, as reflected in plasma Interleukin-6 levels.
Phase:
Phase 2
Details
Lead Sponsor:
Hennepin Healthcare Research Institute Minneapolis Medical Research Foundation